Pfizer's Abrocitinib Looks Competitive In Atopic Dermatitis
The first detailed Phase III results for the company's next-generation oral JAK inhibitor abrocitinib appear to show efficacy on par or better than data from Sanofi/Regeneron's Dupixent and may give Lilly's Olumiant a run for its money in AD.
You may also be interested in...
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
The JAK1 inhibitor showed skin clearance and itch reduction in first of three Phase III trials. Analysts say blockbuster atopic dermatitis indication is possible if data hold up in ongoing studies.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.